Table 3.
Pathologic evaluation n (%)
| L-TME | R-TME | P value | |
| (n = 58) | (n = 53) | ||
| TNM stage | 0.716 | ||
| Stage I | 28 (48.3) | 22 (41.5) | |
| Stage II | 11 (19.0) | 8 (15.1) | |
| Stage III | 13 (22.4) | 18 (34.0) | |
| Pathological complete response | 6 (10.3) | 5 (9.4) | 0.381 |
| Total harvested lymph nodes1 | 11 (3-27) | 18 (4-49) | < 0.001 |
| DRM1 (cm) | 1.5 (0.5-5) | 2.5 (0.5-10) | < 0.001 |
| DRM | 0.729 | ||
| Involved | 1 (1.7) | 1 (1.9) | |
| Non involved | 57 (98.3) | 52 (98.1) | |
| CRM | 0.523 | ||
| Involved | 1 (1.7) | 0 | |
| Non involved | 57 (98.3) | 53 (100) | |
| Lymphovascular invasion | 10 (17.2) | 5 (9.4) | 0.087 |
1
Median (range). L-TME: Laparoscopic total mesorectal excision; R-TME: Robotic total mesorectal excision; DRM: Distal resection margin; CRM: Circumferential resection margin.